FDA greenlights Proteus' wireless personal monitor
The FDA has granted Proteus Biomedical 501(k) clearance for its Raisin Personal Monitor, a wireless personal health device.
According to Redwood City, Calif.-based Proteus, the wearable device has remote reading capabilities for heart patients.
The device allows a patient’s physical activity, body position and patient-logged event data to be logged and sent through a Bluetooth to any computerized device. Data can be sent to a mobile phone and read via the mHealth application.
According to the company, the device is attached to a patient’s skin with an adhesive and worn like a Band-Aid.
Additionally, Proteus said that is has raised $25 million in Series E financing from investors including Medtronic, Novartis and ON Semiconductor, to advance the development and manufacturing of devices focused on aiding cardiovascular disease, infectious diseases and psychiatric disorders.
According to Redwood City, Calif.-based Proteus, the wearable device has remote reading capabilities for heart patients.
The device allows a patient’s physical activity, body position and patient-logged event data to be logged and sent through a Bluetooth to any computerized device. Data can be sent to a mobile phone and read via the mHealth application.
According to the company, the device is attached to a patient’s skin with an adhesive and worn like a Band-Aid.
Additionally, Proteus said that is has raised $25 million in Series E financing from investors including Medtronic, Novartis and ON Semiconductor, to advance the development and manufacturing of devices focused on aiding cardiovascular disease, infectious diseases and psychiatric disorders.